Cell carriers for oncolytic viruses: current challenges and future directions.
Cell carriers for oncolytic viruses: current challenges and future directions.
复制标题
DOI：
10.2147/ov.s36623
复制
发表时间：
2013
影响因子：
6.7
通讯作者：
Bell JC
中科院分区：
文献类型：
--
作者：
Roy DG;Bell JC
临床传播溶瘤病毒的最佳途径被认为是全身静脉注射；然而，免疫系统有几种高效的机制来清除循环系统中的病原体。为了克服通过血流将溶瘤病毒特异性地输送到肿瘤中所面临的挑战，人们对载体细胞进行了研究，以确定它们是否适合作为全身给药溶瘤病毒的输送载体。细胞携带者保护病毒免受中和，这是溶瘤病毒与免疫系统相互作用的最有限的方面之一。细胞携带者还可以具有固有的肿瘤嗜性，从而将病毒更具体地输送到肿瘤。随着临床前研究已经证明了这种方法对多种溶瘤病毒的成功和可行性，对细胞介导的病毒输送的临床评估即将到来。同时，正在进行的临床前研究旨在识别溶瘤病毒的新细胞载体，并改进目前有希望的细胞载体平台。
The optimal route for clinical delivery of oncolytic viruses is thought to be systemic intravenous injection; however, the immune system is armed with several highly efficient mechanisms to remove pathogens from the circulatory system. To overcome the challenges faced in trying to delivery oncolytic viruses specifically to tumors via the bloodstream, carrier cells have been investigated to determine their suitability as delivery vehicles for systemic administration of oncolytic viruses. Cell carriers protect viruses from neutralization, one of the most limiting aspects of oncolytic virus interaction with the immune system. Cell carriers can also possess inherent tumor tropism, thus directing the delivery of the virus more specifically to a tumor. With preclinical studies already demonstrating the success and feasibility of this approach with multiple oncolytic viruses, clinical evaluation of cell-mediated delivery of viruses is on the horizon. Meanwhile, ongoing preclinical studies are aimed at identifying new cellular vehicles for oncolytic viruses and improving current promising cell carrier platforms.